SECISBP2 is a novel prognostic predictor that regulates selenoproteins in diffuse large B-cell lymphoma

The overexpression of glutathione peroxidase 4 (GPX4; an enzyme that suppresses peroxidation of membrane phospholipids) is considered a poor prognostic predictor of diffuse large B-cell lymphoma (DLBCL). However, the mechanisms employed in GPX4 overexpression remain unknown. GPX4 is translated as a...

Full description

Saved in:
Bibliographic Details
Published inLaboratory investigation Vol. 101; no. 2; p. 218
Main Authors Taguchi, Towako, Kurata, Morito, Onishi, Iichiroh, Kinowaki, Yuko, Sato, Yunosuke, Shiono, Sayuri, Ishibashi, Sachiko, Ikeda, Masumi, Yamamoto, Masahide, Kitagawa, Masanobu, Yamamoto, Kouhei
Format Journal Article
LanguageEnglish
Published United States 01.02.2021
Online AccessGet full text

Cover

Loading…
Abstract The overexpression of glutathione peroxidase 4 (GPX4; an enzyme that suppresses peroxidation of membrane phospholipids) is considered a poor prognostic predictor of diffuse large B-cell lymphoma (DLBCL). However, the mechanisms employed in GPX4 overexpression remain unknown. GPX4 is translated as a complete protein upon the binding of SECISBP2 to the selenocysteine insertion sequence (SECIS) on the 3'UTR of GPX4 mRNA. In this study, we investigated the expression of SECISBP2 and its subsequent regulation of GPX4 and TXNRD1 in DLBCL patients. Moreover, we determined the significance of the expression of these selenoproteins in vitro using MD901 and Raji cells. SECISBP2 was positive in 45.5% (75/165 cases) of DLBCL samples. The SECISBP2-positive group was associated with low overall survival (OS) as compared to the SECISBP2-negative group (P = 0.006). Similarly, the SECISBP2 and GPX4 or TXNRD1 double-positive groups (P < 0.001), as well as the SECISBP2, GPX4, and TXNRD1 triple-positive group correlated with poor OS (P = 0.001), suggesting that SECISBP2 may serve as an independent prognostic predictor for DLBCL (hazard ratio (HR): 2.693, P = 0.008). In addition, western blotting showed a decrease in GPX4 and TXNRD1 levels in SECISBP2-knockout (KO) MD901 and Raji cells. Oxidative stress increased the accumulation of reactive oxygen species in SECISBP2-KO cells (MD901; P < 0.001, Raji; P = 0.020), and reduced cell proliferation (MD901; P = 0.001, Raji; P = 0.030), suggesting that SECISBP2-KO suppressed resistance to oxidative stress. Doxorubicin treatment increased the rate of cell death in SECISBP2-KO cells (MD901; P < 0.001, Raji; P = 0.048). Removal of oxidative stress inhibited the altered cell death rate. Taken together, our results suggest that SECISBP2 may be a novel therapeutic target in DLBCL. SECISBP2 overexpression is an independent negative prognostic predictor in diffuse large B-cell lymphoma. Additionally, SECISBP2 positively correlates with selenoprotein expression. In vitro, SECISBP2 knockout increases intracellular reactive oxygen species accumulation via the downregulation of selenoproteins, inhibiting cell growth and promoting cell death after doxorubicin treatment. Therefore, SECISBP2 is a potential therapeutic target for malignant lymphoma.
AbstractList The overexpression of glutathione peroxidase 4 (GPX4; an enzyme that suppresses peroxidation of membrane phospholipids) is considered a poor prognostic predictor of diffuse large B-cell lymphoma (DLBCL). However, the mechanisms employed in GPX4 overexpression remain unknown. GPX4 is translated as a complete protein upon the binding of SECISBP2 to the selenocysteine insertion sequence (SECIS) on the 3'UTR of GPX4 mRNA. In this study, we investigated the expression of SECISBP2 and its subsequent regulation of GPX4 and TXNRD1 in DLBCL patients. Moreover, we determined the significance of the expression of these selenoproteins in vitro using MD901 and Raji cells. SECISBP2 was positive in 45.5% (75/165 cases) of DLBCL samples. The SECISBP2-positive group was associated with low overall survival (OS) as compared to the SECISBP2-negative group (P = 0.006). Similarly, the SECISBP2 and GPX4 or TXNRD1 double-positive groups (P < 0.001), as well as the SECISBP2, GPX4, and TXNRD1 triple-positive group correlated with poor OS (P = 0.001), suggesting that SECISBP2 may serve as an independent prognostic predictor for DLBCL (hazard ratio (HR): 2.693, P = 0.008). In addition, western blotting showed a decrease in GPX4 and TXNRD1 levels in SECISBP2-knockout (KO) MD901 and Raji cells. Oxidative stress increased the accumulation of reactive oxygen species in SECISBP2-KO cells (MD901; P < 0.001, Raji; P = 0.020), and reduced cell proliferation (MD901; P = 0.001, Raji; P = 0.030), suggesting that SECISBP2-KO suppressed resistance to oxidative stress. Doxorubicin treatment increased the rate of cell death in SECISBP2-KO cells (MD901; P < 0.001, Raji; P = 0.048). Removal of oxidative stress inhibited the altered cell death rate. Taken together, our results suggest that SECISBP2 may be a novel therapeutic target in DLBCL. SECISBP2 overexpression is an independent negative prognostic predictor in diffuse large B-cell lymphoma. Additionally, SECISBP2 positively correlates with selenoprotein expression. In vitro, SECISBP2 knockout increases intracellular reactive oxygen species accumulation via the downregulation of selenoproteins, inhibiting cell growth and promoting cell death after doxorubicin treatment. Therefore, SECISBP2 is a potential therapeutic target for malignant lymphoma.
Author Shiono, Sayuri
Yamamoto, Masahide
Ikeda, Masumi
Onishi, Iichiroh
Kitagawa, Masanobu
Kurata, Morito
Taguchi, Towako
Sato, Yunosuke
Kinowaki, Yuko
Ishibashi, Sachiko
Yamamoto, Kouhei
Author_xml – sequence: 1
  givenname: Towako
  surname: Taguchi
  fullname: Taguchi, Towako
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 2
  givenname: Morito
  surname: Kurata
  fullname: Kurata, Morito
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 3
  givenname: Iichiroh
  surname: Onishi
  fullname: Onishi, Iichiroh
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 4
  givenname: Yuko
  surname: Kinowaki
  fullname: Kinowaki, Yuko
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 5
  givenname: Yunosuke
  surname: Sato
  fullname: Sato, Yunosuke
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP; Department of Anesthesiology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 6
  givenname: Sayuri
  surname: Shiono
  fullname: Shiono, Sayuri
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 7
  givenname: Sachiko
  surname: Ishibashi
  fullname: Ishibashi, Sachiko
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 8
  givenname: Masumi
  surname: Ikeda
  fullname: Ikeda, Masumi
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 9
  givenname: Masahide
  surname: Yamamoto
  fullname: Yamamoto, Masahide
  organization: Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 10
  givenname: Masanobu
  surname: Kitagawa
  fullname: Kitagawa, Masanobu
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP
– sequence: 11
  givenname: Kouhei
  surname: Yamamoto
  fullname: Yamamoto, Kouhei
  email: yamamoto.pth2@tmd.ac.jp
  organization: Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, 113-8510, Tokyo, JP. Electronic address: yamamoto.pth2@tmd.ac.jp
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36775487$$D View this record in MEDLINE/PubMed
BookMark eNqFjrsKwjAUQIMoatVfkPsDhdS-nBVFN0H3EtvbNJImITcV_HsddHY6ZzjDidjYWIMjNk_ylMc85eWMRUQPzpMsK_Ipm6VFWebZtpwzeT3sz9fdZQOKQICxT9TgvJXGUlD1R7FRdbAeQicCeJSDFgEJCDUa-ykDKkOgDDSqbQdC0MJLhF1co9agX73rbC-WbNIKTbj6csHWx8Ntf4rdcO-xqZxXvfCv6neW_g3ebN9Gfg
ContentType Journal Article
Copyright Copyright © 2020 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2020 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
DBID NPM
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1530-0307
ExternalDocumentID 36775487
Genre Journal Article
GroupedDBID ---
-Q-
-~X
.55
.GJ
0R~
0SF
1KJ
29L
2WC
36B
39C
3V.
4.4
53G
5GY
5RE
70F
7X7
88E
8AO
8C1
8FI
8FJ
8R4
8R5
8WZ
A6W
AALRI
AANZL
AAXUO
AAZLF
ABAWZ
ABCQX
ABJNI
ABLJU
ABUWG
ACGFO
ACGFS
ACIWK
ACKTT
ACPRK
ACRQY
ACZOJ
ADBBV
ADHDB
ADVLN
AEJRE
AENEX
AEXYK
AFFNX
AFJKZ
AFKRA
AFOSN
AFRAH
AFSHS
AGAYW
AGEZK
AGHAI
AHMBA
AHSBF
AILAN
AITUG
AJRNO
AKRWK
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
DIK
DNIVK
DU5
E3Z
EBS
EE.
EIOEI
EJD
EMB
F5P
FDB
FDQFY
FEDTE
FERAY
FIZPM
FSGXE
FYUFA
GX1
HCIFZ
HMCUK
HVGLF
HZ~
IH2
IWAJR
JSO
KQ8
M1P
M7P
MVM
NAO
NPM
NQJWS
O9-
OK1
P2P
P6G
PQQKQ
PROAC
PSQYO
Q2X
RNS
RNT
RNTTT
ROL
S10
SNX
SNYQT
SOHCF
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TR2
TSG
TWZ
UKHRP
X7M
Y6R
YFH
YKV
YOC
YQI
YQT
ZGI
ZXP
ID FETCH-pubmed_primary_367754873
IngestDate Wed Oct 16 00:38:58 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Copyright © 2020 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-pubmed_primary_367754873
PMID 36775487
ParticipantIDs pubmed_primary_36775487
PublicationCentury 2000
PublicationDate 2021-Feb
PublicationDateYYYYMMDD 2021-02-01
PublicationDate_xml – month: 02
  year: 2021
  text: 2021-Feb
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Laboratory investigation
PublicationTitleAlternate Lab Invest
PublicationYear 2021
SSID ssj0014465
Score 4.3774767
Snippet The overexpression of glutathione peroxidase 4 (GPX4; an enzyme that suppresses peroxidation of membrane phospholipids) is considered a poor prognostic...
SourceID pubmed
SourceType Index Database
StartPage 218
Title SECISBP2 is a novel prognostic predictor that regulates selenoproteins in diffuse large B-cell lymphoma
URI https://www.ncbi.nlm.nih.gov/pubmed/36775487
Volume 101
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1LT8JAEIA3ggnhYny_yR68NTWFPoCjEAxqJEQwwRPZ1pY04i4pRaO_3pnttgUjiXppSLds2n7N7MzsPAi58AIb9DYfLNXAcnTLt5neaDZMPYDFNqg7TWa4Msq353QfrduRPcqbccrskti99D5_zCv5D1U4B1wxS_YPZLNJ4QT8Br5wBMJw_BXjQad9M2j1a9iVnGlcvPlTGXDFBVZfxvz_5xCd8qBdsliLkrbz_lzDDktcyBINYRJIjn1SFnNfm2JguNbS0Z-vTT8AtVCCO8uZlh8N7syHeYmOfC9_yCbYXkV-BuKdvYilvSKWaKr3IgIxknl3OXrBpKgK4Y-RyPzTdyHHGeTY00LNpBwUtWoa04zrSypUDR2FyYrUVZeES9ZvKkMby7IdXvnsVQI0HSzXp9bn1SLZ6VCBFMyqXSSbrU6v_5BtJ2FVuDIppVd9MyGkKjHcJlvKBqBXCdAdsuHzXVK6V1EOe2SScqXhnDIqudKcK824UuRKM650lSsNOVVcqeRKE6405bpPKtedYburJ7c5niWVR8bpA5gHpMgF948IBX0MbD54xJrBLMOqu57jmTaqoUYAxrFzTA7XTHKyduSUlHOQZ6QYRwv_HHSv2K2oN_sF_pw76g
link.rule.ids 315,783,787
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SECISBP2+is+a+novel+prognostic+predictor+that+regulates+selenoproteins+in+diffuse+large+B-cell+lymphoma&rft.jtitle=Laboratory+investigation&rft.au=Taguchi%2C+Towako&rft.au=Kurata%2C+Morito&rft.au=Onishi%2C+Iichiroh&rft.au=Kinowaki%2C+Yuko&rft.date=2021-02-01&rft.eissn=1530-0307&rft.volume=101&rft.issue=2&rft.spage=218&rft_id=info%3Apmid%2F36775487&rft.externalDocID=36775487